GNSC Genaissance Pharmaceuticals (MM)

Genaissance Pharmaceuticals Comments on Stock Activity NEW HAVEN, Conn., April 28 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) today commented that nothing fundamental in the Company's operations has changed to cause the current market activity in its Common Stock. As a reminder, Genaissance will host a conference call on Tuesday, May 3, 2005, at 11:00 a.m. Eastern time in conjunction with the release of its financial results for the first quarter ended March 31, 2005. Genaissance will be presenting at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference in Paris, France, at 3:30 p.m. local time (9:30 a.m. Eastern time) on Wednesday, May 4, 2005. Genaissance Pharmaceuticals, Inc. is developing innovative products based on its proprietary pharmacogenomic technology and has a revenue-generating business in DNA and pharmacogenomic products and services. Genaissance also markets its proprietary FAMILION(TM) Test, designed to detect mutations responsible for causing Familial Long QT and Brugada Syndromes, two causes of sudden cardiac death. The Company's product development strategy is focused on drug candidates with promising clinical profiles and finding genetic markers to identify a responsive patient population. This strategy is designed to enable Genaissance to leverage existing clinical data and, thus, reduce the costs and risks associated with traditional drug development and increase the probability of clinical success and commercialization. The Company's lead therapeutic product, vilazodone for depression, is in Phase II of development. For more information on Genaissance, visit the Company's website at: http://www.genaissance.com/. DATASOURCE: Genaissance Pharmaceuticals, Inc. CONTACT: Kevin Rakin, President & Chief Executive Officer, Genaissance Pharmaceuticals, Inc., +1-203-773-1450; or Rhonda Chiger (investors), Rx Communications Group, +1-917-322-2569; or Tom Redington (media), Redington, Inc., +1-203-222-7399, for Genaissance Pharmaceuticals Web site: http://www.genaissance.com/

Copyright